However, anti-cancer vaccines show significant potential if used to prevent tumor growth in healthy patients at a “high-risk” of developing a cancer—i.e., people with occupational exposure to carcinogens [66], or hereditary mutations in breast cancer (BRCA) genes [67], or in p53 [68], etc.—and when treating recurrence and metastasis in cancer patients with minimal residual disease. The gene discussed is TP53; the disease is cancer.